InsidersTradesSigma
Track the SI-BONE, Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, SI-BONE, Inc. has published 280 reports. Market capitalisation: €872.6m. The latest transaction was filed on 26 August 2026 (Cession). Among the most active insiders: Maheshwari Anshul. The full history is accessible without an account.
280
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€12m
193 ops.
Sell Volume
57Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,357 of 29,056 companies
35.8
score / 100
Value30
Quality42
FCF yld-1.1%
Earn yld-2.2%
EV/EBITDA·
ROE-8.3%
Gross mgn80%
Net mgn-9.4%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 26 August 2026
Declarations280 total
25,972 shares@ US$20.1215Common StockSEC:0001218802-26-000005:0
11,636 shares@ US$19.960.027% mcap41.3% of flowCommonSEC144:0001950047-26-008605
3,923 shares@ US$19.480.0086% mcap6.9% of flowCommonSEC144:0001950047-26-008557
11,228 shares@ US$19.480.025% mcap66.3% of flowCommonSEC144:0001950047-26-008520
51,884 shares@ US$19.460.11% mcap33.1% of flowCommon StockSEC:0001218802-26-000004:0
3,923 shares@ US$20.020.0088% mcap2.6% of flowCommon StockSEC:0001218802-26-000004:1
5,747 shares@ US$19.550.013% mcap5.9% of flowCommon StockSEC:0001853089-26-000007:0
11,228 shares@ US$20.020.025% mcap11.7% of flowCommon StockSEC:0001853089-26-000007:1
51,884 shares@ US$19.910.12% mcap100.0% of flowCommonSEC144:0001950047-26-008468
5,747 shares@ US$19.140.012% mcap100.0% of flowCommonSEC144:0001950047-26-008408
1,854 shares@ US$18.61540.0041% mcap5.4% of flowCommon StockSEC:0001754765-26-000006:0
1,871 shares@ US$18.65210.0041% mcap5.4% of flowCommon StockSEC:0001754765-26-000006:1
3,203 shares@ US$18.6630.0070% mcap3.1% of flowCommon StockSEC:0001218802-26-000003:2
3,892 shares@ US$18.65780.0086% mcap3.7% of flowCommon StockSEC:0001218802-26-000003:0
3,652 shares@ US$18.65950.0080% mcap3.5% of flowCommon StockSEC:0001218802-26-000003:1
2,236 shares@ US$18.68140.0049% mcap2.1% of flowCommon StockSEC:0001218802-26-000003:3
1,973 shares@ US$18.62890.0043% mcap1.9% of flowCommon StockSEC:0001218802-26-000003:4
2,476 shares@ US$18.67980.0055% mcap2.9% of flowCommon StockSEC:0001853089-26-000006:0
2,189 shares@ US$18.62240.0048% mcap2.6% of flowCommon StockSEC:0001853089-26-000006:1
20,000 shares@ US$4.680.011% mcap2.3% of flowCommon StockSEC:0001035986-26-000005:0
20,000 shares@ US$18.46070.045% mcap9.2% of flowCommon StockSEC:0001035986-26-000005:1
1,799 shares@ US$16.69920.0038% mcap57.4% of flowCommon StockSEC:0001754765-26-000005:0
34 shares@ US$16.860.0001% mcap1.1% of flowCommon StockSEC:0001754765-26-000005:1
1,757 shares@ US$16.80170.0038% mcap3.1% of flowCommon StockSEC:0001853089-26-000005:0
1,560 shares@ US$16.73480.0033% mcap2.8% of flowCommon StockSEC:0001853089-26-000005:1
25 of 280 declarations
关于 SI-BONE, Inc.
SI-BONE, Inc. 是一家在美国纳斯达克上市的美国医疗设备公司。该公司专注于骶骨盆和肌肉骨骼疾病，特别强调骶髂 (SI) 关节功能障碍和相关的融合手术。SI-BONE 于 2008 年在特拉华州成立，总部位于加利福尼亚州圣克拉拉，其业务围绕一个临床差异化的植入平台和在骨科手术利基领域强大的循证定位而建立。其早期的领导地位来自于 iFuse 系统，这是一种用于 SI 关节融合的微创三角形植入物，帮助公司成为该领域的早期先行者。([investor.si-bone.com](https://investor.si-bone.com/static-files/56c626d7-ed89-4866-8e5e-a4fa04e47f7a?utm_source=openai)) 从运营角度来看，SI-BONE 向外科医生、医院和门诊护理提供商销售手术解决方案，而不是作为一家大型骨科企业集团运营。其产品组合现在已超越最初的 iFuse 平台，包括 iFuse-3D、iFuse TORQ、iFuse Bedrock Granite 和 iFuse INTRA 等。这种产品线的扩展具有重要的战略意义：管理层一直在将公司从单一产品的故事重新定位为更广泛的“受损骨骼”解决方案平台，该平台可以解决骨盆、创伤和脊柱相邻节段的其他临床应用。([investor.si-bone.com](https://investor.si-bone.com/static-files/56c626d7-ed89-4866-8e5e-a4fa04e47f7a?utm_source=openai)) 在竞争方面，SI-BONE 的护城河基于先发优势、悠久的临床记录、外科医生教育以及公司积累的监管和报销经验。在一个医生采纳和付款人覆盖至关重要的专业市场中，SI-BONE 强调已发表的临床数据、FDA 批准和持续的产品迭代作为差异化的来源。该业务仍主要由美国驱动，但也在国际上扩张，包括在欧洲的推出和在美国以外更广泛的商业活动。([investor.si-bone.com](https://investor.si-bone.com/news-releases/news-release-details/si-bone-inc-announces-publication-5-year-follow-data-ifuse?utm_source=openai)) 最近的发展支持了增长叙事。2025 年，SI-BONE 报告了强劲的收入增长，并强调了盈利能力的改善，以及有利的报销进展。该公司还通过新产品发布和产品线扩展继续扩大其产品组合，同时宣布与 Smith+Nephew 达成一项分销协议，以改善某些解决方案的市场准入。对于股票投资者而言，SI-BONE 最好被视为一家创新驱动的专业医疗技术公司，拥有专注的特许经营权、不断增长的国际足迹以及与产品采纳、报销和商业扩张相关的多个执行催化剂。([investor.si-bone.com](https://investor.si-bone.com/news-releases/news-release-details/si-bone-inc-reports-record-financial-results-fourth-quarter-2025/?utm_source=openai))
